Item request has been placed!
×
Item request cannot be made.
×
Processing Request
[Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Bartal A;Bartal A; Mátrai Z; Szûcs A; Liszkay G
- Source:
Magyar onkologia [Magy Onkol] 2011 Jun; Vol. 55 (2), pp. 91-8. Date of Electronic Publication: 2011 Mar 07.
- Publication Type:
Journal Article; Review
- Language:
Hungarian
- Additional Information
- Transliterated Title:
A daganatterápia egyik dermatológiai mellékhatása, a kéz-láb szindróma fõbb kezelési és megelõzési elvei.
- Source:
Publisher: Professional Publishing Hungary Kft Country of Publication: Hungary NLM ID: 9313833 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0025-0244 (Print) Linking ISSN: 00250244 NLM ISO Abbreviation: Magy Onkol Subsets: MEDLINE
- Publication Information:
Publication: Budapest : Professional Publishing Hungary Kft.
Original Publication: Budapest : Medicina, [1957-
- Subject Terms:
- Abstract:
Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil. It affects the skin of the palms and soles manifesting characteristic symptoms like erythema, inflammation, dysesthesia, pain, thickening, desquamation and cracking of the skin that may progress to cause wounds and ulceration, negatively influencing quality of life, psychological state and belief in recovery, which often result in the need of permanent or temporary interruption of the oncologic treatment and are potential sources of danger to the completion of the therapy. Adequate provision of the syndrome is of particular importance since a decline in adherence due to adverse events endangers precise maintenance of the self-sufficient oral treatment at home. Early recognition of symptoms, regular oncologic checkups and patient education on how to prevent or soothe the unpleasant skin toxicities could ensure a more successful treatment.
- Accession Number:
0 (Antineoplastic Agents)
0 (Taxoids)
04079A1RDZ (Cytarabine)
0W860991D6 (Deoxycytidine)
15H5577CQD (Docetaxel)
6804DJ8Z9U (Capecitabine)
80168379AG (Doxorubicin)
U3P01618RT (Fluorouracil)
- Publication Date:
Date Created: 20110610 Date Completed: 20110817 Latest Revision: 20181201
- Publication Date:
20231215
- Accession Number:
MagyOnkol.2011.55.2.91
- Accession Number:
21655474
No Comments.